Lycium barbarum polysaccharide alleviates IL-1β-evoked chondrogenic ATDC5 cell inflammatory injury through mediation of microRNA-124.

Lycium barbarum polysaccharide (LBP) is a promising therapeutic drug in inflammation-related injuries, nevertheless the mechanism of LBP's action is still elusive. The study is to explore the effect of LBP on IL-1β-evoked ATDC5 cell inflammatory injury. ATDC5 cells were administrated with 10 ng/mL interleukin (IL)-1β to establish an model of cartilage damage. After management, cell viability was tested through CCK8 assay. The pro-inflammatory cytokines and cyclooxygenase (Cox)-2 were assessed through ELISA, western blot and qRT-PCR. MiR-124 expression in ATDC5 cells was silenced by transfecting with miR-124 inhibitor, and the pro-inflammatory cytokines and Cox-2 were re-assessed. NF-κB and JNK pathways were measured through western blot. IL-1β stimulation accelerated the release of IL-1β, IL-6 and TNF-α, elevated Cox-2 expression. LBP significantly eased IL-1β-induced inflammation. MiR-124 expression was observed to enhance by LBP, and the impacts of LBP on ATDC5 cells were lightened via transfection with miR-124 inhibitor. NF-κB and JNK pathways were activated after IL-1β stimulation, nevertheless were inactivated by LBP administration. Besides, LBP-evoked the repression of NF-κB and JNK pathways were overturned by miR-124 inhibitor. Our study suggests that LBP protects ATDC5 cells from IL-1β-evoked injury through up-regulating miR-124 via blocking NF-κB and JNK pathways.